Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 1042

Next Previous
Drug Profile

GEN 1042

Alternative Names: BNT-312; DuoBody-CD40x4-1BB; DuoBody-CD40xCD137; GEN-1042; IgG1 Fc-silenced bispecific antibody - BioNTech/Genmab

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech; Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; CD40 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Sep 2023 Genmab plans a phase-I trial for Solid tumours (Monotherapy, Combination therapy) in Japanese patients (IV) (NCT06057038)
  • 14 Apr 2023 Pharmacodynamics data from a preclinical trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 01 Feb 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater) in France (Intratumoural) (NCT05491317)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top